Mestag Therapeutics
Founded 2020 · 40 employees on LinkedIn · 6 known investors
Find your way into Mestag Therapeutics
694 people in our graph share verified history with the Mestag Therapeutics team — schools, employers, funds. One of them is your warm intro.
Anthony Philippakisunlockedknows Susan Hill · together at University of Cambridge (overlapped)
knows the team · via Mestag Therapeutics
×3knows the team · via Cornell
×3knows the team · via University of California, Berkeley
knows the team · via Merck Serono
×2knows the team · via University of Cambridge
Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets. It advances its own pipeline while partnering with pharmaceutical companies such as MSD and Johnson & Johnson.
Founders & leadership
SH
Susan HillinChief Executive OfficerSusan Hill has over 25 years of experience in biotech, pharma, and investment, including roles in biotech consulting, venture investing, business development, and operating positions in venture-backed companies. She founded and has served as CEO of Mestag Therapeutics through multiple funding rounds and partnerships since its inception.
MB
Michael B. BrennerFounder
CB
Chris BuckleyFounder
MC
Mark ColesinFounderMark Coles leads the Stromal and Systems Immunology Group at the Kennedy Institute of Rheumatology, where his research combines experimental and computational methods to study immune function in inflammatory diseases, tissue fibrosis, and cancer. He also directs the Digital Pathology Omics Core at Oxford, providing multiplex imaging services.
SR
Soumya RaychaudhuriFounder
DA
David A. TuvesonFounder
LR
Lindsey RolfeinChief Medical Officer
PM
Pascal MerchiersinChief Development Officer
RD
Robert de JongeinChief Business Officer
GE
Greg ElsonHead of CMC
Investors · 6
Funding
SEC filings, press & company announcements$40M disclosed across 1 of 2 rounds · 2026
- $40MraisedMar 2026 · 5 sources
Forbion, GV, JJDC, Northpond Ventures, SV Health Investors
Source ↗ - Undisclosed amountseed financingApr 2021Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Founder mafia
3 people who came through Mestag Therapeutics went on to found or lead other companies.
In the news
Frequently asked questions
- What does Mestag Therapeutics do?
- Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets. It advances its own pipeline while partnering with pharmaceutical companies such as MSD and Johnson & Johnson.
- Who founded Mestag Therapeutics?
- Mestag Therapeutics was founded by Susan Hill, Michael B. Brenner, Chris Buckley, Mark Coles, Soumya Raychaudhuri, David A. Tuveson in 2020.
- Who are Mestag Therapeutics's investors?
- Mestag Therapeutics's investors include GV (Google Ventures), Forbion, Johnson & Johnson Innovation – JJDC, Northpond Ventures, SV Health Investors, JJDC.
- How much funding has Mestag Therapeutics raised?
- Mestag Therapeutics has disclosed $40M raised across 1 of its 2 known rounds.